Androgen Deprivation Therapy Does Not Keep Localized Prostate Cancer From Spreading, New Study Says

  • May 26th, 2008
    • |
  • Erectile dysfunction medication
    • |
  • No Comments

    • erectile dysfunction drugs

    Science Daily — Oregon Health & Science University Cancer Institute researchers wanted to know if depriving men of erectile dysfunction herbal medication actually keeps cancer from spreading beyond the prostate. What they found is that men who have localized prostate cancer with certain high-risk features and receive this treatment — known as androgen deprivation therapy — remain at risk of dying from prostate cancer.

    “The notion that androgen deprivation therapy will hold prostate cancer at bay while you die of something else is not proving to be entirely true,” said Tomasz Beer, M.D., director of the Prostate Cancer Research Program in the Oregon Health & Science University Cancer Institute.

    This is especially important because recent studies of physician practice trends show that androgen deprivation therapy is being used with increased frequency for men with prostate cancer that has not spread.

    “Reasons for this trend are not really known, but may include a desire to do something rather than do nothing on the part of both physicians and patients,” Beer said. “Unfortunately, these men may be enduring significant side effects for an uncertain benefit.”

    Androgen deprivation therapy, also known as hormone therapy, is the gold standard of care for men whose prostate cancer is advanced and has spread throughout the body. The therapy works by shutting down male hormones, principally testosterone, that can promote prostate cancer growth. This common treatment for prostate cancer wipes out most male hormones found in the body. Side effects can be significant and include erectile dysfunction, hot flashes, fatigue, impotence org, high cholesterol, anemia, erectile dysfunction impotence medication and insomnia.

    Little is known about the effectiveness of hormonal therapy in men whose cancer remains localized within the prostate, so Beer and his colleagues decided to study data from the Prostate Cancer Outcome Study (PCOS). They presented their results on Saturday, Feb. 25, at the Prostate Cancer Symposium in San Francisco.

    In the retrospective study, the research team examined demographic data, socio-economic factors and tumor biology in relationship to overall survival and cancer-specific survival for a subgroup of 276 PCOS subjects who had localized prostate cancer and received androgen deprivation therapy as their primary treatment. Between 1994 and 1995, a total of 3,486 men were enrolled in PCOS within six months of prostate cancer diagnosis.

    The analysis showed that out all the demographic and socio-economic factors considered, overall survival was predicted only by age and certain features of prostate cancer. Tumor biology, which is measured by Gleason score, was the only independent predictor of cancer specific survival. Tumor mass as measured by PSA approached statistical new erectile dysfunction medication as a predictor. Nearly 10 percent of men died from prostate cancer within 5 years of starting hormonal therapy.

    “Our study indicates that cancer remains an important contributor to overall mortality in these men, erectile dysfunction impotence medication those with high Gleason score and high serum PSA,” Beer said. “These data will be useful for men with localized prostate cancer choosing between aggressive treatments such as surgery or radiation, observation and androgen deprivation therapy.”

    In an earlier OHSU Cancer Institute study of the effectiveness of hormone deprivation as a primary therapy for localized prostate cancer, researchers found that younger men and those with higher-grade tumors are more likely to experience disease progression during treatment. They also found that men with localized prostate cancer on hormone therapy experience a higher than expected rate of bone fractures caused primarily by treatment-related osteoporosis.

    “Studies suggest that more needs to be known about the risks and benefits of this treatment before we recommend it to patients with localized disease,” Beer said.

    Prostate cancer is the most common cancer in men and the second leading cause of cancer-related death in American men. Overall, 1 in 6 men will develop prostate cancer during his lifetime.

    ###

    This study was funded by the National Cancer Institute, a component of the National Institutes of Health.

    Particulars:
    Abstract No. 291: Predictors of Overall and Cancer-Specific Survival in Patients with Clinically Localized Prostate Cancer (PC) Treated with Primary Androgen Deprivation Therapy (PADT): Results from the Prostate Cancer Outcomes Study.

    Authors: Julie N. Graff, Motomi Mori, Hong Li, Mark Garzotto, David Penson, Arnold Potosky and Tomasz M. Beer.

    Note: This story has been adapted from material provided by Oregon Health & Science University.

    Read another articles about erectile dysfunction edmedicine.

    Botulism Bug Says No To Nitric Oxide, Provides Key To Molecule’s Role In Human Cell Signaling

  • May 25th, 2008
    • |
  • Erectile dysfunction medication
    • |
  • No Comments

    • erectile dysfunction drugs

    Science Daily — HOUSTON (Oct. 7, 2004) — A deadly bacterium’s defense against a mortal molecular enemy illuminates the origins and structure of a vital protein involved in human cell signaling, University of Texas Medical School scientists report today in Science Express, the rapid online publication forum for the journal Science.

    The paper also details how evolution transformed one of nature’s simplest molecules, nitric oxide (NO), from a toxin to anaerobic bacteria the planet’s oldest life form into a beneficial signaling molecule in higher animals. It also offers an explanation for how the decades-old practice of treating meat with sodium nitrite prevents alternative treatment for erectile dysfunction food poisoning known as botulism.

    Discovering how botulism-causing Clostridium botulinum detects nitric oxide (NO) sheds light on how NO connects with its receptor protein in humans to govern crucial processes in the cardiovascular, neurological and immunological systems, said senior author C. S. Raman, Ph.D., assistant professor and director of the Structural Biology Research Center in the UT Medical School Department of Erectile dysfunction impotence medication and Molecular Biology.

    “We started by identifying the protein that the botulism bug uses to detect and evade NO,” Raman said. “What we have ultimately shown is how this protein evolved from being part of a protective mechanism into a system that learned to use the toxin to benefit the organism.”

    In human beings, nitric oxide binds to a receptor called soluble guanylyl cyclase to make cyclic GMP, a molecule that improves blood flow by relaxing blood vessel walls. Ferid Murad, M.D., Ph.D., professor and chairman of Integrative Biology and Pharmacology at the UT Medical School at Houston, won the Nobel prize for his 1977 finding that NO is the ingredient that makes more erectile dysfunction symptom
     beneficial to heart patients. Since then NO has been found to govern many other vital biological functions and became the basis for medications that treat erectile dysfunction.

    However, the structural details of soluble guanylyl cyclase have remained elusive, Murad and Raman said. The protein is difficult to crystallize for structural analysis.

    During a series of experiments that tracked the dysfunction help
     development of the sensor protein identified in C. botulinum, dubbed SONO for “sensor of NO,” the scientists were able to determine the condition dysfunction erectile more symptom
     structure of a related nitric oxide sensor in a different bacterium.

    That structure will provide a key to unlock answers to some questions regarding the human NO receptor, soluble guanylyl cyclase (sGC), Raman said. “Having these structures now will help us attack that problem, because we know that this bacterial version of SONO is very similar to soluble guanylyl cyclase.

    “If you know the structure of a protein, then you can develop therapeutics targeted to detect specific binding pockets on the molecule,” Raman said. “That may allow us to control sGC activity in the absence of nitric oxide in such a way that we can combat cardiovascular and cerebrovascular disease.”

    And don’t forget meat protection. The research team showed that C. botulinum uses SONO to detect nitric oxide, and then to flee its presence. “It’s a strange topic for a strict vegetarian who has never touched meat in his life,” Raman said.

    Co-authors of the paper are: First author Pierre Nioche, Ph.D., research fellow in the Structural Biology Research Center; Vladimir Berka, Ph.D., senior research associate and Ah-Lim Tsai, Ph.D., professor, both of the Medical School Division of Hematology; and from the United Kingdom, Julia Vipond of the Health Protection Agency, Porton Down, Salisbury; and Nigel Minton of the Center of Biomolecular Sciences and Institute of Infection, Immunity and Inflammation, University of Nottingham.

    Note: This story has been adapted from material provided by University Of Texas Health Science Center At Houston.

    erectile dysfunction drugs, and more another.

    Penn Surgeons Use Completely Robotic Surgery To Treat Prostate Cancer

  • May 24th, 2008
    • |
  • Erectile dysfunction medication
    • |
  • No Comments

    • erectile dysfunction drugs

    Science Daily —

    PHILADELPHIA, PA Prostate cancer is the second leadingcause of death among American men. It is estimated that one in sixmales will develop the disease during his lifetime. However, promisingnew treatment options have been developed to help combat thisthreatening disease.


    At the console, David I. Lee, MD, operates the four robotic arms, which include movable “wrists,” using hand and foot controls. One of the robotic arms holds a tiny video camera, one works as a retractor and the other two replicate the surgeon's exact hand movements. (Image courtesy of University of Pennsylvania School of Medicine)

    One of the most innovative of thesetreatments is robotic-assisted laparoscopic prostatectomy (removal ofthe prostate). The University of Pennsylvania Health System iscurrently one of only a handful of facilities across the countryoffering this minimally invasive, high-tech treatment. David I. Lee,M.D., a national expert in robotic surgery, was recruited to Penn andnamed Chief of the Division of Urology at Penn Presbyterian MedicalCenter, where the robotic prostate program is based.

    There aremany factors that make robotics an exceptionally valuable tool in theoperating room during prostate surgery, for both the patient andsurgeon. “Perhaps two of the most-feared possible long-term effects ofa radical prostatectomy are erectile dysfunction and condition dysfunction erectile more symptom
    ,” says Dr. Lee. “My specially-trained team and I havediscovered that by using the robotic technique there is greater nervesparing, which provides patients with the best chance for maintainingpotency and continence.”

    Robotic technology offers a number ofadvantages during surgery. For instance, the robotic “arms” filter evenminute tremors of the human hand so to provide steadiness. The robot’scamera also provides a erectile dysfunction impotence medication, stereoscopic image of thebody’s interior, as opposed to a two-dimensional image on a flatscreen. This improved perspective enables depth perception thatsharpens the visualization of the prostate and the network of nervesand tissue surrounding it. Additionally, by scaling down the motion ofthe robotic instruments, the surgeon can perform extremely precise,intricate movements during the procedure. For example, if the surgeon’shand moves five centimeters, he/she can scale the robotic hand to moveonly one centimeter.

    Robotic technology also offers a number ofadvantages after surgery. Because laparoscopic surgery is minimallyinvasive and no large incisions are involved, robotic-assisted woman impotence numerous benefits for prostate cancer patients, including:less pain and scarring, diminished blood loss, a shorter hospital stayand reduced recovery period for a quicker return to daily activities.

    Theactual robot consists of a tower that manipulates condition dysfunction
     from a console that is situated a few feet from the patient.At the console, the surgeon operates four robotic “arms” and “wrists”using hand and foot controls. One of the robotic arms holds a tinyvideo camera, one works as a retractor and the other two replicate thesurgeon’s exact hand movements. The camera and instruments are insertedthrough small keyhole incisions in the patient’s abdomen. The surgeonthen directs the robotic instruments to dissect the prostate gland andsurrounding tissue.

    Unlike standard laparoscopic approaches thatrequire counter-intuitive movements by surgeons (whereby the surgeonmust move his hand to the left in order to move the mechanical deviceto the right), the robotic technology affords surgeons the direct,”intuitive” control they exercise in traditional open surgicalprocedures, seamlessly translating their natural hand, wrist and fingermovements at the console into corresponding micro-movements oflaparoscopic surgical instruments inside the patient’s body.

    Pennhas been using fully robotic surgery for cardiac patients for the pastthree years and is currently studying its use for head and neck over the counter erectile dysfunction medication. “The robotic prostate program is a continuation of Penn’scommitment to finding and applying the most precise, most beneficialsurgical techniques to put patients on a quicker road to recovery withbetter outcomes,” said Dr. Lee.

    Note: This story has been adapted from material provided by University of Pennsylvania School of Medicine.

    How do yo think, is it true about erectile dysfunction drugs?

    Men In Their 50s Have More Satisfying Sex Lives Than Men In Their 30s

  • May 23rd, 2008
    • |
  • Erectile dysfunction medication
    • |
  • No Comments

    • erectile dysfunction drugs

    Science Daily — Men in their fifties are more satisfied with their sex lives than men in their thirties and forties, recording similar levels to 20-29 year-olds, according to a survey published in the February issue of BJU International.

    A team of experts from Norway and the USA surveyed 1,185 men aged between 20 and 79, asking them about various aspects of their sex life, including drive, erections and ejaculation.

    They found that although there was a strong erectile dysfunction help
     between a man’s advancing age and his declining sex drive and ability to have an erection and ejaculate, there wasn’t such a strong link between age and overall sexual satisfaction.

    The men who responded to the Norwegian postal questionnaire were asked to rate their satisfaction with various aspects of their sex life on a scale of zero to four, with four dysfunction erectile symptom
     good sexual function and no problems. Men in their twenties recorded an average overall satisfaction level of 2.79 and the second highest level was among fifty-somethings who recorded an average of 2.77. Men in their 30s only reached 2.55 and men in their forties averaged 2.72.

    After the age of 59, overall satisfaction fell natural remedy for erectile dysfunction
     to 2.46 for men in their sixties and 2.14 for men in their seventies.

    However when it came to sexual function, each of the scores moved steadily downwards toward zero as the respondents got older, indicating lower levels of function and more problems:

    • The average score for sexual drive was 2.19 out of four, ranging from 2.79 for men in the twenties to 1.54 for men in their seventies.
    • Satisfaction with erections averaged 2.83, dropping sharply once men reached their fifties. Men in their twenties scored 3.63, men in their fifties 3.03 and men in their seventies 1.60.
    • Ejaculation averaged 3.28 and showed a more measured decline with age, falling more sharply for men in their sixties and seventies. Men in their twenties averaged 3.85 while men in their seventies averaged 2.32.

    Other findings included:

    • 86 per cent of the men surveyed were married or in a sexual relationship and 57 per cent had been sexually active in the last 30 days. Six per cent had had a new sexual partner in the last six months.
    • 25 per cent were on medication for high blood pressure, five per cent for diabetes, six per cent for anxiety/depression and five per cent for erectile dysfunction.
    • Respondents were representative of the Norwegian male population in terms of marital status and education level.

    “The survey was carried out using a questionnaire first developed and tested in American in 1995″ says co-author Professor Sophie D Fossa from the Over the counter erectile dysfunction medication Trust in Oslo, who carried out the research with colleagues from the University of Oslo, the University of Bergen and Harvard Medical School in the USA.

    “The results showed a very strong correlation between men getting older and reduced sexual functioning, but not between age and sexual satisfaction” she points out.

    “Age accounted for a 22 per cent variance in sexual drive, a 33 per cent variance in erection issues and a 23 per cent variance in ejaculation issues.

    “But age only accounted for a variance of three per cent in overall satisfaction.

    “Our results show that although men experience more problems and less sexual function as they get older, it doesn’t necessarily follow that they are less satisfied with their sex lives as a result.”

    ###

    Notes:
    Assessment of male sexual function by the Brief Sexual Function Inventory. Mykletun, Dahl, O’Leary and Fossa. Norway / USA. BJU International. Volume 97, pages 316 to 323. (February 2006).

    Established in 1929, BJU International is published 12 times a year by Blackwell Publishing and edited by Professor John Fitzpatrick from University College Dublin, Ireland. It provides its international readership with invaluable practical information on all aspects of urology, including original and alternative treatment for erectile dysfunction articles and illustrated surgery. www.bjui.org

    Note: This story has been adapted from material provided by Blackwell Publishing Ltd..

    Read more about erectile dysfunction medicine.

    Gene Therapy Delivery Of Nerve Growth Factors Reverses Erectile Dysfunction In Animal Model

  • May 22nd, 2008
    • |
  • Erectile dysfunction medication
    • |
  • No Comments

    • erectile dysfunction drugs

    Science Daily — Rats with erectile dysfunction, or ED, that were injected with a gene therapy vector containing either of two nerve growth factors were able to regain normal function after four weeks, according to a study conducted by University of Pittsburgh School of Medicine new treatment for erectile dysfunction. These findings are being presented at the 10th annual meeting of the American Society of Gene Therapy, which is convening May 30 to June 3 at the Washington State Convention & Trade Center, Seattle.

    ED is the repeated inability to achieve or maintain an erection necessary for sexual intercourse. Because of the variability of symptoms, estimates of the incidence of ED vary but range from 15 million to 30 million affected men in the United States. ED is frequently associated with damage to the cavernous nerve that results from surgery for prostate cancer. Even if a patient receives a nerve-sparing procedure during surgery, recovery from ED after radical prostatectomy may take a long time.

    In this study, which was led by Joseph C. Glorioso, III, Ph.D., chair of the department of biochemistry and molecular genetics, and Joel Nelson, M.D., chair of the department of urology, University of Pittsburgh School of Medicine, researchers inserted either the gene for the glial cell line derived neurotrophic factor (GDNF) or the GDNF family ligand (neurturin) into a genetically engineered herpes simplex virus (HSV). They then injected either of the recombinant viruses into the damaged cavernous nerve of rats. GDNF is an important nerve growth promoter and has been shown in other studies to contribute to survival and regeneration of penile nerves. Neurturin also is a nerve growth factor closely related to GDNF. Control mice received only the virus without the GDNF or neurterin genes inserted.

    Four weeks after the treatment, rats administered HSV-GDNF exhibited male sexual dysfunction recovery of intracavernous pressure (ICP) and systemic arterial pressure (AP) compared with rats treated with the control virus or untreated mice with ED. Rats treated with HSV-neurturin also exhibited significant recovery of ICP and AP compared with the control or untreated mice at four weeks after treatment. Fluorescent protein studies also showed that the delivered genes had been effectively natural cure for erectile dysfunction into the target nerve cells.

    According to Dr. Glorioso, HSV delivery of GDNF or neurturin presents a potentially important new approach for the treatment of ED. “Because the herpes virus persists in the nerve cell for as long as it is alive and nerve cells typically do not reproduce, this represents the first-ever demonstration of a long-term treatment for ED that does not rely on the chronic administration of drugs that can have potentially harmful side effects,” he explained.

    In addition to Drs. Glorioso and Nelson, others involved in the study included, William F. Goins, Ph.D., Shaohua Huang, Ph.D., James B. Wechuck, Ph.D., and Darren P. Wolfe, Ph.D., department of molecular genetics and biochemistry, University of Pittsburgh School of Medicine; Ryuichi Kato, M.D., Naoki Yoshimura, M.D., Christian H. Coyle, M.D., Michael B. Chancellor, M.D., and Fernando de Miguel, M.D., department of urology, University of Pittsburgh School of Medicine; and Taiji Tsukamoto, M.D., department of urology, Sapparo Medical University School of Medicine, Japan.

    Note: This story has been adapted from material provided by University of Pittsburgh Schools of the Health Sciences.

    See related site about erectile dysfunction drugs.

    Testosterone Deficiency Relatively Rare In Men

  • May 21st, 2008
    • |
  • Erectile dysfunction medication
    • |
  • No Comments

    • erectile dysfunction drugs

    Science Daily — A new study reveals that relatively few men, only 5.6 percent of the male population, actually suffer from low testosterone accompanied by clinical symptoms. That percentage, however, rises erectile help with age.

    Low testosterone levels are typically defined as less than 300 ng/dL (nanograms per deciliter) of total testosterone and less than 5 ng/dL of free testosterone. Free testosterone is the amount of the hormone unbound to other proteins and is “free” to work inside the body. “Low levels of testosterone impact many aspects of male physiology,” said Andre B. Araujo, Ph.D., a research scientist at the New England Research Institutes in Watertown, Mass., and lead author of the study. “This is new treatment for erectile dysfunction impotence herbs
     because the ongoing aging of the U.S. male population is likely to cause the number of men suffering from androgen deficiency to increase appreciably.”

    Consistent with a recently issued Clinical Practice Guideline from the Endocrine Society, symptomatic androgen deficiency in the study by Araujo and colleagues is defined as low total and free testosterone plus the presence of low libido, erectile dysfunction, osteoporosis or facture, or two or more of the following symptoms: sleep disturbance, depressed mood, lethargy, or diminished physical performance.

    For this study, the researchers analyzed data on 1,475 randomly selected men enrolled in the Boston Area Community Health (BACH) Survey. The survey tracked subjects between the ages of 30-79 and compiled complete data on factors such as testosterone, symptoms of hormone deficiency, and medications that may impact sex hormone levels. Among all men in the study (mean age 47.3 plus-or-minus 12.5 years), erectile dysfunction help
     24 percent had low total testosterone and 11 percent had low levels of free testosterone. Interestingly, while low testosterone levels were associated with symptoms, many men with low testosterone levels were asymptomatic (e.g., among men aged 50 years and older 47.6 percent were asymptomatic).

    “Since these men would not likely come to clinical attention,” said Araujo, “it may be important to determine whether there are clinical risks to missing these asymptomatic men with low testosterone levels.” Overall, only 5.6 percent of men in the study had symptomatic androgen deficiency. For those men in the upper range of ages in the study (70 years or older), however, the percentage increased to 18.4 percent.

    The researchers predicted that by the year 2025 there may be as many as 6.5 million American men 30-79 years of age with symptomatic androgen deficiency, an increase of 38 percent from year 2000 population estimates.

    “This study did not assess whether men with symptomatic androgen deficiency are good candidates for testosterone therapy,” said Araujo. “Well designed randomized placebo-controlled trials would be needed to address the risks and benefits of testosterone therapy.”

    The BACH Survey was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (Grant DK 56842). Analyses for the current study were supported through an unrestricted educational grant from GlaxoSmithKline.

    A rapid release version of this paper has been published on-line and will appear in the November 2007 issue of the Journal of Clinical Endocrinology & Metabolism, a alternative treatment for erectile dysfunction of The Endocrine Society.

    Note: This story has been adapted from material provided by Endocrine Society.

    Read another articles about erectile dysfunction edmedicine.

    Decreased Genital Sensation In Competitive Women Cyclists

  • May 20th, 2008
    • |
  • Erectile dysfunction medication
    • |
  • No Comments

    • erectile dysfunction drugs

    Science Daily — Women who participated in prolonged, frequent bicycling had decreased genital sensation and were more likely to have a history of genital pain than women runners, researchers in the Department of Obstetrics, Gynecology & Erectile help Sciences at Yale School of Medicine and The Albert Einstein College of Medicine report in the current issue of the Journal of Sexual Medicine.

    The researchers compared 48 women competitive cyclists to 22 women runners. They used non-invasive techniques to evaluate the possible effects of bicycling on genital sensation and sexual health. New erectile dysfunction medication in the study were women bicyclists who consistently rode an average of at least 10 miles per week, four weeks per month. Women who ran at least one mile daily or five miles weekly were chosen as a control group because they represent an active group of women who were not exposed to direct pressure in the perineal region.

    “We found that competitive women cyclists have a decrease in genital sensation. However, there were no negative effects on sexual function and quality of life in our young, healthy erectile dysfunction help
     study participants,” said lead author Marsha K. Guess, M.D., assistant professor of obstetrics and gynecology at Yale.

    About 13 million American women bicycle regularly, according to statistics cited in the article. While health benefits of bicycling are many, the activity has also been linked to injuries and fatalities due to motor vehicle collisions, neck and back pain, and chafing, folliculitis, and other ailments that affect both sexes. Past studies, including one authored by National Institute for Occupational Safety and Health co-investigator Steve Schrader, have found an association between bicycling and erectile dysfunction and genital numbness in men.

    “This is the first study to evaluate the effects of prolonged or frequent bicycling on herbal remedy for erectile dysfunction and sexual function in women,” said Guess. “While seated on a bicycle, the external genital nerve and artery are directly compressed. It is possible that chronic compression of the female genital area may lead to medication that cause erectile dysfunction blood flow and nerve injury due to disruption of the blood-nerve barrier.”

    Co-author Kathleen Connell, M.D., assistant professor of Obstetrics and Gynecology at Yale published an article last year in The American Journal of Obstetrics and Gynecology showing that loss of genital sensation was associated with sexual dysfunction. However, Connell notes, “This study did not address the long-term effects of bicycling on genital sensation or on women’s sexual health in this study.”

    In addition to Guess and Connell, other authors on the study included Steven Schrader, Ph.D., Susan Reutman Ph.D., Andrea Wang, M.D., Julie LaCombe, M.D., Christine Toennis, Brian Lowe, Ph.D. Arnold Melman, M.D., and Magdy Mikhail, M.D.

    Citation: J Sex Med, Vol. 3 , 6 949-1101 (November 2006)

    Note: This story has been adapted from material provided by Yale University.

    erectile dysfunction medicine

    Mayo Researchers Find Link Between Lower Urinary Tract Symptoms And Sexual Dysfunction In Older Men

  • May 18th, 2008
    • |
  • Erectile dysfunction medication
    • |
  • No Comments

    • erectile dysfunction drugs

    Science Daily — ROCHESTER, Minn. — Mayo Clinic researchers report in the latest issue of Mayo Clinic Proceedings that there may be an association between lower urinary tract symptoms and sexual dysfunction among older men. As the population ages, this finding will help further research that could help millions of men.

    Lower urinary tract symptoms become common as men age and their prostates enlarge, restricting urine flow or altering their bladder habits. At this same age (age 65 and older) an estimated 100 million men worldwide experience erectile dysfunction. The Mayo Clinic researchers set out to determine whether the urinary tract symptoms and sexual dysfunction are related or not.

    This observation suggests there may be a common cause that someday may prove amenable to medical treatments that could be effective for treating both conditions, says Steven Jacobsen, M.D., Ph.D., a Mayo Clinic researcher and the senior author of the study in the June 2004 issue of Mayo Clinic Proceedings.

    The researchers studied 2,115 male patients in The Olmsted County Study of Urinary Symptoms and Health Status Among Men. The men, ages 40 to 79, completed questionnaires in 1990 and were followed up every two years. Dr. Jacobsen says the study in Mayo Clinic Proceedings is one of the few community-based studies to assess the medication that cause erectile dysfunction between the symptoms of sexual dysfunction and lower urinary tract symptoms. In contrast, other studies examined only the association between individual urinary symptoms and sexual life dysfunction and lower urinary tract symptoms in selected patients who underwent medical or surgical treatments.

    The symptoms that were most strongly associated with sexual dysfunction included a feeling of urgency, having to get up multiple times at night, a weak urine stream and straining to start urinating. These symptoms were all associated with difficulties with getting or maintaining erections, feeling of problems with sexual function and satisfaction. However, they were not strongly associated with sex drive after taking age differences into account.

    ###

    Other authors of the study are: Woo-Sik Chung, M.D., Ajay Nehra, M.D., Debra Jacobson, Rosebud Roberts, M.B., Ch.B, Thomas Rhodes, Cynthia Girman, DrPH, and Michael Lieber, M.D. Dr. Girman and Mr. Rhodes are employees of Merck & Co., Inc. The research was funded in part by the U.S. Public Health Services National Institutes of Health and Merck Research Erectile dysfunction
    .

    A cure dysfunction erectile journal, Mayo Clinic Proceedings publishes original articles and reviews dealing with clinical and laboratory medicine, clinical research, basic science research and clinical epidemiology. Mayo Clinic Proceedings is published monthly by Mayo Foundation for Education and Research as part of its commitment to the medical education of physicians. The journal has been published for more than 75 years and has a circulation of 130,000 nationally and internationally. A copy of the article will be available online after the embargo lifts at http://www.mayo.edu/proceedings.

    Note: This story has been adapted from material provided by Mayo Clinic.

    See related site about erectile dysfunction medicine.

    Study Finds Men With Enlarged Prostate Can Benefit From Botox Injections

  • May 17th, 2008
    • |
  • Erectile dysfunction medication
    • |
  • No Comments

    • erectile dysfunction drugs

    Science Daily — When researchers at the Chang Gung University Medical College, Taiwan and the University of Pittsburgh School of Medicine injected botulinum toxin A, or Botox, into the prostate gland of men with benign prostatic over the counter erectile dysfunction medication (BPH), a condition commonly referred to as enlarged prostate, they found that it eased symptoms and improved quality of life. Their results, based on 41 men with the condition, will be presented at the annual meeting of the American Urological Association (AUA) in Atlanta and published in abstract 1436 in the AUA proceedings.

    “Millions of men in the United States suffer from enlarged prostate,” said Michael B. Chancellor, M.D., professor of urology and gynecology at the University of Pittsburgh School of Medicine. “It’s a herbal impotence treatment disease to live with because it causes frequent and difficult urination. Unfortunately, common treatments also are new treatment for erectile dysfunction because they carry some risk of serious side effects, such as impotence. Our results are encouraging because they indicate that Botox could represent a simple, safe and effective treatment for enlarged prostate.”

    The patients, ranging in age from 49 to 79 years, with symptomatic BPH that did not respond to standard medical treatment, received injections of Botox directly into their prostate glands. Thirty-one patients, or 75.6 percent, experienced a 30 percent improvement in urinary tract symptoms and quality of life. These improvements were seen up to one year post-injection in some of the patients. Four out of five patients, or 80 percent, were able to completely empty their bladders within a week to one month after the injection, as the Botox caused the prostate gland to relax, putting less pressure on the urethra. Patients did not experience any significant side effects, including stress urinary cause and treatment of erectile dysfunction or erectile dysfunction.

    According to Dr. Chancellor, Botox reduces the size of the prostate gland through a cellular process called apoptosis, in which the prostate cells die in a programmed manner. This reduction in size can improve urine flow and decrease residual urine left in the bladder.

    BPH is one of the most common diseases affecting men as they age. More than half of all men over the age of 60, and 80 percent by age 80, will have enlarged prostates. Forty to 50 percent will develop symptoms of BPH, which include more frequent urination, urinary tract infections, the inability to completely empty the bladder and, in severe cases, eventual damage to the bladder and kidneys.

    Cure dysfunction erectile natural to the study include Yao-Chi Chuang, M.D., Po-Hui Chiang, M.D., and Kaohsiung Hsien, M.D., with the Chang Gung University Medical College, Taiwan; and Naoki Yoshimura M.D., Ph.D., and Fernando de Miguel, Ph.D., with the University of Pittsburgh School of Medicine. The study is funded by a grant from Allergan.

    Note: This story has been adapted from material provided by University of Pittsburgh Medical Center.

    edmedicine, and more another.

    Men With Enlarged Prostate Can Benefit From Botox Injections Up To A Year After Treatment

  • May 16th, 2008
    • |
  • Erectile dysfunction medication
    • |
  • No Comments

    • erectile dysfunction drugs

    Science Daily — Injecting botulinum toxin A, or Botox, into the prostate gland of men with enlarged prostate, eased symptoms and improved quality of life up to a year after the procedure, according to a study by researchers at the Chang Gung University Medical College, Taiwan, and the University of Pittsburgh School of Medicine. The study, based on 37 men with benign prostatic hyperplasia (BPH), was presented at the annual meeting of the American Urological Association (AUA) in Anaheim, Calif. and published in Abstract 1837 in the AUA proceedings.

    “Millions of men in the United States suffer from enlarged prostate,” said Michael B. Chancellor, M.D., senior author of the study and professor of urology and gynecology at the University of Pittsburgh School of Medicine. “It’s a challenging disease to live with because it causes frequent and difficult urination. Erection penis problem
    , common treatments also are problematic because they carry some risk of serious side effects, such as impotence. Our results are erection penis problem
     because they indicate that Botox could represent a simple, safe and effective treatment for enlarged prostate that has long-term benefits.”

    The study erectile dysfunction home remedy, previously diagnosed with symptomatic BPH that did not respond to standard medical treatment, received injections of Botox directly into their prostate glands. Up to one year post injection, 27 of these patients, or 73 percent, experienced a 30 percent improvement in urinary tract symptoms and quality of life. Patients did not experience any condition dysfunction erectile more treatment side effects, including stress urinary incontinence or erectile dysfunction.

    According to Yao-Chi Chuang, M.D., principal investigator of the study from Chang Gung University Medical College, Taiwan, Botox reduces the size of the prostate gland through a cellular process called apoptosis, in which the prostate cells die in a programmed manner. This reduction in size can improve urine flow and decrease residual urine left in the bladder.

    BPH is one of the most common diseases affecting men as they age. More than half of all men over the age of 60 and 80 percent by age 80, will have enlarged prostates. Forty to 50 percent will develop symptoms, which include more frequent urination, urinary tract infections, the inability to completely empty the bladder and, in severe cases, eventual damage to the bladder and kidneys.

    Contributors to the study include Po-Hui Chiang, M.D., and Kaohsiung Hsien, M.D., with the Chang Gung University Medical College, Taiwan; and Naoki Yoshimura M.D., Ph.D., with the University of Pittsburgh School of Medicine. The study is funded by a grant from Allergan.

    Note: This story has been adapted from material provided by University of Pittsburgh Schools of the Health Sciences.

    How do yo think, is it true about erectile dysfunction medicine?

    Previous Entries